Philippe Chanson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/46280/publications.pdf

Version: 2024-02-01

283 papers	19,683 citations	6613 79 h-index	14758 127 g-index
298 all docs	298 docs citations	298 times ranked	11844 citing authors

#	Article	IF	Citations
1	A Consensus on Criteria for Cure of Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3141-3148.	3.6	697
2	A Family with Hypogonadotropic Hypogonadism and Mutations in the Gonadotropin-Releasing Hormone Receptor. New England Journal of Medicine, 1997, 337, 1597-1603.	27.0	473
3	A Consensus Statement on acromegaly therapeutic outcomes. Nature Reviews Endocrinology, 2018, 14, 552-561.	9.6	382
4	GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. Journal of Hepatology, 2012, 56, 184-191.	3.7	354
5	Clinical Characteristics and Therapeutic Responses in Patients with Germ-LineAIPMutations and Pituitary Adenomas: An International Collaborative Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E373-E383.	3.6	323
6	The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. European Journal of Endocrinology, 2011, 165, 383-392.	3.7	322
7	Impact of Growth Hormone (GH) Treatment on Cardiovascular Risk Factors in GH-Deficient Adults: A Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2192-2199.	3.6	321
8	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology,the, 2021, 9, 847-875.	11.4	315
9	Expert consensus document: A consensus on the medical treatment of acromegaly. Nature Reviews Endocrinology, 2014, 10, 243-248.	9.6	306
10	Gigantism and Acromegaly Due to Xq26 Microduplications and GPR101 Mutation. New England Journal of Medicine, 2014, 371, 2363-2374.	27.0	292
11	MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2012, 18, 2828-2837.	7.0	277
12	Pituitary Apoplexy. Endocrine Reviews, 2015, 36, 622-645.	20.1	270
13	Place of Cabergoline in Acromegaly: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1327-1335.	3.6	255
14	Isolated Familial Hypogonadotropic Hypogonadism and aGNRH1Mutation. New England Journal of Medicine, 2009, 360, 2742-2748.	27.0	247
15	Acromegaly. Nature Reviews Disease Primers, 2019, 5, 20.	30.5	247
16	Ketoconazole in Cushing's Disease: Is It Worth a Try?. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1623-1630.	3.6	231
17	TAC3andTACR3Defects Cause Hypothalamic Congenital Hypogonadotropic Hypogonadism in Humans. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2287-2295.	3.6	214
18	Outcome of Gamma Knife Radiosurgery in 82 Patients with Acromegaly: Correlation with Initial Hypersecretion. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4483-4488.	3.6	209

#	Article	IF	Citations
19	Endocrine Aspects of Obstructive Sleep Apnea. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 483-495.	3.6	202
20	Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4592-4599.	3.6	202
21	Germ-Line Mutation Analysis in Patients with Multiple Endocrine Neoplasia Type 1 and Related Disorders. American Journal of Human Genetics, 1998, 63, 455-467.	6.2	197
22	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. European Journal of Endocrinology, 2018, 178, 265-276.	3.7	196
23	A Critical Analysis of Pituitary Tumor Shrinkage during Primary Medical Therapy in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4405-4410.	3.6	193
24	Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1500-1508.	3.6	191
25	Octreotide Therapy for Thyroid-Stimulating Hormone-Secreting Pituitary Adenomas: A Follow-up of 52 Patients. Annals of Internal Medicine, 1993, 119, 236.	3.9	189
26	Acromegaly. Orphanet Journal of Rare Diseases, 2008, 3, 17.	2.7	188
27	Mitotane, Metyrapone, and Ketoconazole Combination Therapy as an Alternative to Rescue Adrenalectomy for Severe ACTH-Dependent Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2796-2804.	3.6	187
28	Multidisciplinary management of acromegaly: A consensus. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 667-678.	5.7	183
29	New insights in prolactin: pathological implications. Nature Reviews Endocrinology, 2015, 11, 265-275.	9.6	178
30	Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. European Journal of Endocrinology, 2012, 167, 651-662.	3.7	173
31	Growth Hormone, Insulin-Like Growth Factor-1, and the Kidney: Pathophysiological and Clinical Implications. Endocrine Reviews, 2014, 35, 234-281.	20.1	171
32	Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. European Journal of Endocrinology, 2010, 163, 193-200.	3.7	167
33	Long-Term Results of Stereotactic Radiosurgery in Secretory Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3400-3407.	3.6	164
34	Acromegaly at diagnosis in 3173 patients from the LiÃ¨ge Acromegaly Survey (LAS) Database. Endocrine-Related Cancer, 2017, 24, 505-518.	3.1	164
35	RecurrentPRKAR1AMutation in Acrodysostosis with Hormone Resistance. New England Journal of Medicine, 2011, 364, 2218-2226.	27.0	162
36	Germline AIP Mutations in Apparently Sporadic Pituitary Adenomas: Prevalence in a Prospective Single-Center Cohort of 443 Patients. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E663-E670.	3.6	157

#	Article	IF	Citations
37	Cardiac Effects of Growth Hormone in Adults With Growth Hormone Deficiency. Circulation, 2003, 108, 2648-2652.	1.6	155
38	Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocrine-Related Cancer, 2015, 22, 745-757.	3.1	155
39	Acromegaly and McCune-Albright Syndrome. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1955-1969.	3.6	149
40	Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. European Journal of Endocrinology, 2005, 152, 61-66.	3.7	148
41	Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clinical Endocrinology, 2006, 65, 536-543.	2.4	142
42	Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. European Journal of Endocrinology, 2011, 164, 877-884.	3.7	140
43	Management of clinically non-functioning pituitary adenoma. Annales D'Endocrinologie, 2015, 76, 239-247.	1.4	136
44	Cinacalcet Reduces Serum Calcium Concentrations in Patients with Intractable Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2766-2772.	3.6	134
45	Impact of Somatostatin Analogs on the Heart in Acromegaly: A Metaanalysis. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1743-1747.	3.6	133
46	Acromegaly. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 555-574.	4.7	133
47	Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. European Journal of Endocrinology, 2017, 176, 645-655.	3.7	133
48	The diagnostic value of fine-needle aspiration biopsy under ultrasonography in nonfunctional thyroid nodules: A prospective study comparing cytologic and histologic findings. American Journal of Medicine, 1994, 97, 152-157.	1.5	128
49	Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. European Journal of Endocrinology, 2007, 157, 1-8.	3.7	127
50	Cardiovascular Effects of the Somatostatin Analog Octreotide in Acromegaly. Annals of Internal Medicine, 1990, 113, 921.	3.9	125
51	Testicular Anti-MÃ¼llerian Hormone Secretion Is Stimulated by Recombinant Human FSH in Patients with Congenital Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 724-728.	3.6	122
52	Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary, 2014, 17, 81-89.	2.9	122
53	Pregnancy outcomes following cabergoline treatment: extended results from a 12â€year observational study. Clinical Endocrinology, 2008, 68, 66-71.	2.4	120
54	Reference Values for IGF-I Serum Concentrations: Comparison of Six Immunoassays. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3450-3458.	3.6	118

#	Article	IF	Citations
55	Panhypopituitarism as a Model to Study the Metabolism of Dehydroepiandrosterone (DHEA) in Humans¹. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2578-2585.	3.6	116
56	APRKAR1AMutation Associated with Primary Pigmented Nodular Adrenocortical Disease in 12 Kindreds. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1943-1949.	3.6	116
57	The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best Practice and Research in Clinical Endocrinology and Metabolism, 2019, 33, 101290.	4.7	115
58	THERAPY OF ENDOCRINE DISEASE: Outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. European Journal of Endocrinology, 2015, 172, R227-R239.	3.7	114
59	Prevalence of Metabolic Syndrome in Adult Hypopituitary Growth Hormone (GH)-Deficient Patients Before and After GH Replacement. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 74-81.	3.6	113
60	Efficacy of the Long-Acting Octreotide Formulation (Octreotide-Lar) in Patients with Thyrotropin-Secreting Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2849-2853.	3.6	112
61	Acromegaly and Pregnancy: A Retrospective Multicenter Study of 59 Pregnancies in 46 Women. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4680-4687.	3.6	111
62	Clinical Pharmacokinetics of Octreotide. Clinical Pharmacokinetics, 1993, 25, 375-391.	3.5	110
63	Kallmannâ€™s Syndrome: A Comparison of the Reproductive Phenotypes in Men Carrying KAL1 and FGFR1/KAL2 Mutations. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 758-763.	3.6	109
64	Frequent Large GermlineHRPT2Deletions in a French National Cohort of Patients With Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E403-E408.	3.6	107
65	Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. European Journal of Endocrinology, 2017, 176, 769-777.	3.7	107
66	Non-syndromic congenital hypogonadotropic hypogonadism: clinical presentation and genotypeâ€“phenotype relationships. European Journal of Endocrinology, 2010, 162, 835-851.	3.7	104
67	Normal Pituitary Hypertrophy as a Frequent Cause of Pituitary Incidentaloma: A Follow-Up Study. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3009-3015.	3.6	101
68	Metabolic Syndrome in Cushingâ€™s Syndrome. Neuroendocrinology, 2010, 92, 96-101.	2.5	99
69	Pituitary Magnetic Resonance Imaging Findings Do Not Influence Surgical Outcome in Adrenocorticotropin-Secreting Microadenomas. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3371-3376.	3.6	94
70	Functional hypothalamic amenorrhoea: a partial and reversible gonadotrophin deficiency of nutritional origin. Clinical Endocrinology, 1999, 50, 229-235.	2.4	92
71	McCuneâ€“Albright syndrome and acromegaly: clinical studies and responses to treatment in five cases. European Journal of Endocrinology, 1994, 131, 229-234.	3.7	90
72	Long-Term Outcome of Patients with Acromegaly and Congestive Heart Failure. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5308-5313.	3.6	89

#	Article	IF	Citations
73	Current management practices for acromegaly: an international survey. Pituitary, 2011, 14, 125-133.	2.9	89
74	MAFA missense mutation causes familial insulinomatosis and diabetes mellitus. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1027-1032.	7.1	88
75	Epithelial Sodium Channel Is a Key Mediator of Growth Hormone-Induced Sodium Retention in Acromegaly. Endocrinology, 2008, 149, 3294-3305.	2.8	86
76	Genetic mutations in sporadic pituitary adenomasâ€"what to screen for?. Nature Reviews Endocrinology, 2015, 11, 43-54.	9.6	86
77	Panhypopituitarism as a Model to Study the Metabolism of Dehydroepiandrosterone (DHEA) in Humans. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2578-2585.	3.6	86
78	Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. European Journal of Endocrinology, 2015, 172, 473-481.	3.7	84
79	Macroprolactinomas in Children and Adolescents: Factors Associated With the Response to Treatment in 77 Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1177-1186.	3.6	83
80	Normosmic Congenital Hypogonadotropic Hypogonadism Due to TAC3/TACR3 Mutations: Characterization of Neuroendocrine Phenotypes and Novel Mutations. PLoS ONE, 2011, 6, e25614.	2.5	83
81	Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis. Endocrine-Related Cancer, 2010, 17, 361-371.	3.1	81
82	Clinical Characteristics and Outcome of Acromegaly Induced by Ectopic Secretion of Growth Hormone-Releasing Hormone (GHRH): A French Nationwide Series of 21 Cases. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2093-2104.	3.6	81
83	Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe dâ€™Ã©tude des Tumeurs Endocrines (GTE) cohort study. Human Molecular Genetics, 2013, 22, 1940-1948.	2.9	81
84	Osteoblastic cells derived fronm isolated lesions of fibrous dysplasia contain activating somatic mutatuions of thje Gsî± gene. Human Molecular Genetics, 1995, 4, 1675-1676.	2.9	78
85	Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocrine-Related Cancer, 2015, 22, 169-177.	3.1	78
86	AntimÃ¼llerian Hormone in Patients with Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2696-2699.	3.6	77
87	Female Gonadal Function before and after Treatment of Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4518-4525.	3.6	77
88	Type A Insulin Resistance Syndrome Revealing a Novel Lamin A Mutation. Diabetes, 2005, 54, 1873-1878.	0.6	75
89	Hepatobiliary and Pancreatic Neoplasms in Patients With McCune-Albright Syndrome. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E97-E101.	3.6	75
90	Effects of Human Recombinant Luteinizing Hormone and Follicle-Stimulating Hormone in Patients with Acquired Hypogonadotropic Hypogonadism: Study of Sertoli and Leydig Cell Secretions and Interactions. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3239-3244.	3.6	72

#	Article	IF	Citations
91	Macimorelin as a Diagnostic Test for Adult GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3083-3093.	3.6	71
92	Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study. BMJ: British Medical Journal, 1998, 316, 1132-1133.	2.3	70
93	Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clinical Endocrinology, 2000, 53, 445-451.	2.4	70
94	Control of IGFâ€Ł levels with titrated dosing of lanreotide Autogel over 48Âweeks in patients with acromegaly. Clinical Endocrinology, 2008, 69, 299-305.	2.4	70
95	Primary hyperparathyroidism in pregnancy. Endocrine, 2013, 44, 591-597.	2.3	65
96	Cardiac Structure and Function in Cushing's Syndrome: A Cardiac Magnetic Resonance Imaging Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2144-E2153.	3.6	65
97	Post-surgical management of non-functioning pituitary adenoma. Annales D'Endocrinologie, 2015, 76, 228-238.	1.4	65
98	National acromegaly registries. Best Practice and Research in Clinical Endocrinology and Metabolism, 2019, 33, 101264.	4.7	65
99	Clinical aspects of multiple endocrine neoplasia type 1. Nature Reviews Endocrinology, 2021, 17, 207-224.	9.6	64
100	Antimullerian Hormone in Patients with Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2696-2699.	3.6	64
101	Cardiac Effects of Growth Hormone Treatment in Chronic Heart Failure: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 180-185.	3.6	63
102	Non-invasive Diagnostic Strategy in ACTH-dependent Cushingâ€™s Syndrome. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3273-3284.	3.6	62
103	Biochemical characterization of a Ca2+/NAD(P)H-dependent H2O2 generator in human thyroid tissue. Biochimie, 1999, 81, 373-380.	2.6	61
104	Parental Origin of G_sÎ± Mutations in the McCune-Albright Syndrome and in Isolated Endocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3007-3009.	3.6	61
105	Comparison of fast Fourier transform and autoregressive spectral analysis for the study of heart rate variability in diabetic patients. International Journal of Cardiology, 2005, 104, 307-313.	1.7	60
106	Prevalence and Incidence of Diabetes Mellitus in Adult Patients on Growth Hormone Replacement for Growth Hormone Deficiency: A Surveillance Database Analysis. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2255-2261.	3.6	60
107	The Antigonadotropic Activity of a 19-Nor-Progesterone Derivative Is Exerted Both at the Hypothalamic and Pituitary Levels in Women. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4191-4196.	3.6	57
108	No Evidence of a Detrimental Effect of Cabergoline Therapy on Cardiac Valves in Patients with Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1714-E1719.	3.6	57

#	Article	IF	Citations
109	SAGITÂ®: clinician-reported outcome instrument for managing acromegaly in clinical practiceâ€"development and results from a pilot study. Pituitary, 2016, 19, 39-49.	2.9	56
110	Anti-MÃ¼llerian Hormone and Ovarian Morphology in Women With Isolated Hypogonadotropic Hypogonadism/Kallmann Syndrome: Effects of Recombinant Human FSH. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1102-1111.	3.6	55
111	McCune-Albright Syndrome and Acromegaly: Effects of Hypothalamopituitary Radiotherapy and/or Pegvisomant in Somatostatin Analog-Resistant Patients. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4957-4961.	3.6	54
112	Endocrine Effects of the Tyrosine Kinase Inhibitor Vandetanib in Patients Treated for Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2741-2749.	3.6	54
113	Management of hyperglycaemia in Cushing's disease: Expertsâ€™ proposals on the use of pasireotide. Diabetes and Metabolism, 2013, 39, 34-41.	2.9	54
114	Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocrine-Related Cancer, 2010, 17, 797-807.	3.1	52
115	Signs and symptoms of acromegaly at diagnosis: the physicianâ€™s and the patientâ€™s perspectives in the ACRO-POLIS study. Endocrine, 2019, 63, 120-129.	2.3	51
116	A new FSHÎ² mutation in a 29-year-old woman with primary amenorrhea and isolated FSH deficiency: functional characterization and ovarian response to human recombinant FSH. European Journal of Endocrinology, 2010, 162, 633-641.	3.7	50
117	High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. European Journal of Endocrinology, 2012, 166, 261-268.	3.7	50
118	Body Fluid Expansion in Acromegaly Is Related to Enhanced Epithelial Sodium Channel (ENaC) Activity. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2127-2135.	3.6	49
119	Pathophysiology of Renal Calcium Handling in Acromegaly: What Lies behind Hypercalciuria?. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2124-2133.	3.6	48
120	Management of nonfunctioning pituitary incidentaloma. Annales D'Endocrinologie, 2015, 76, 191-200.	1.4	48
121	Cabergoline in acromegaly. Pituitary, 2017, 20, 121-128.	2.9	48
122	Pitfall of Petrosal Sinus Sampling in a Cushing's Syndrome Secondary to Ectopic Adrenocorticotropin-Corticotropin Releasing Hormone (ACTH-CRH) Secretion. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 305-308.	3.6	48
123	Prevalence ofKISS1 Receptormutations in a series of 603 patients with normosmic congenital hypogonadotrophic hypogonadism and characterization of novel mutations: a single-centre study. Human Reproduction, 2016, 31, 1363-1374.	0.9	47
124	The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas. Journal of Neurosurgery, 1989, 71, 687-690.	1.6	46
125	Management of pituitary apoplexy. Expert Opinion on Pharmacotherapy, 2004, 5, 1287-1298.	1.8	46
126	Integrated Genomic Profiling Identifies Loss of Chromosome 11p Impacting Transcriptomic Activity in Aggressive Pituitary PRL Tumors. Brain Pathology, 2011, 21, 533-543.	4.1	46

#	Article	IF	Citations
127	Insulin-like Peptide 3 (INSL3) in Men With Congenital Hypogonadotropic Hypogonadism/Kallmann Syndrome and Effects of Different Modalities of Hormonal Treatment: A Single-Center Study of 281 Patients. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E268-E275.	3.6	46
128	Impact of Successful Treatment of Acromegaly on Overnight Heart Rate Variability and Sleep Apnea. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2925-2931.	3.6	46
129	Pituitary Apoplexy. Endocrinology and Metabolism Clinics of North America, 2015, 44, 199-209.	3.2	46
130	Decreased regional blood flow in patients with acromegaly. Clinical Endocrinology, 1998, 49, 725-731.	2.4	45
131	Long-term results of the surgical management of insulinoma patients with MEN1: a Groupe d'Ã©tude des Tumeurs Endocrines (GTE) retrospective study. European Journal of Endocrinology, 2015, 172, 309-319.	3.7	44
132	Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. European Journal of Endocrinology, 2015, 173, 693-702.	3.7	44
133	Very low frequency of germline GPR101 genetic variation and no biallelic defects with AIP in a large cohort of patients with sporadic pituitary adenomas. European Journal of Endocrinology, 2016, 174, 523-530.	3.7	44
134	Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1. Annals of Surgery, 2020, 272, 1094-1101.	4.2	44
135	RAPID IMPROVEMENT IN SLEEP APNOEA OF ACROMEGALY AFTER SHORT-TERM TREATMENT WITH SOMATOSTATIN ANALOGUE SMS 201-995. Lancet, The, 1986, 327, 1270-1271.	13.7	43
136	Genomic Alterations and Complex Subclonal Architecture in Sporadic GH-Secreting Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1929-1939.	3.6	43
137	Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly. Pituitary, 2000, 2, 269-276.	2.9	42
138	Diagnostic tests for Cushing's syndrome differ from published guidelines: data from ERCUSYN. European Journal of Endocrinology, 2017, 176, 613-624.	3.7	42
139	Rapidly Reversible Myocardial Edema in Patients with Acromegaly: Assessment with Ultrafast T2 Mapping in a Single-Breath-Hold MRI Sequence. American Journal of Roentgenology, 2008, 190, 1576-1582.	2.2	40
140	Acromegaly. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 124, 197-219.	1.8	40
141	Worse Healthâ€Related Quality of Life at longâ€term followâ€up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the <scp>ERCUSYN</scp>. Clinical Endocrinology, 2018, 88, 787-798.	2.4	40
142	Sex-Related Differences in Lactotroph Tumor Aggressiveness Are Associated With a Specific Gene-Expression Signature and Genome Instability. Frontiers in Endocrinology, 2018, 9, 706.	3.5	40
143	Cardiovascular findings and management in Turner syndrome: insights from a French cohort. European Journal of Endocrinology, 2012, 167, 517-522.	3.7	39
144	Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea. Journal of the Endocrine Society, 2017, 1, 1362-1371.	0.2	38

#	Article	IF	Citations
145	Adrenal GIPR expression and chromosome 19q13 microduplications in GIP-dependent Cushingâ€™s syndrome. JCI Insight, 2017, 2, .	5.0	38
146	Preoperative medical treatment in Cushingâ€™s syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. European Journal of Endocrinology, 2018, 178, 399-409.	3.7	37
147	The 2016â€“2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. European Journal of Cancer, 2020, 130, 39-50.	2.8	37
148	The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS) Tj ETQq0 0 0 rgBT /Overlock 10 T	3.7	36
149	68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5843-5852.	3.6	36
150	Non-responsiveness of serum gonadotropins and testosterone to pulsatile GnRH in hemochromatosis suggesting a pituitary defect. European Journal of Endocrinology, 1993, 128, 351-354.	3.7	35
151	Congenital hypogonadotropic hypogonadism in females: Clinical spectrum, evaluation and genetics. Annales D'Endocrinologie, 2010, 71, 158-162.	1.4	34
152	Growth Hormone Response to Oral Glucose Load: From Normal to Pathological Conditions. Neuroendocrinology, 2019, 108, 244-255.	2.5	34
153	How can we minimise the use of regular oral corticosteroids in asthma?. European Respiratory Review, 2020, 29, 190085.	7.1	34
154	Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study. Lancet Diabetes and Endocrinology,the, 2021, 9, 813-824.	11.4	34
155	Severe hyponatremia as a frequent revealing sign of hypopituitarism after 60 years of age. European Journal of Endocrinology, 2003, 149, 177-178.	3.7	33
156	Lessons From McCune-Albright Syndromeâ€“Associated Intraductal Papillary Mucinous Neoplasms. JAMA Surgery, 2014, 149, 858.	4.3	33
157	D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly. European Journal of Endocrinology, 2009, 161, 231-235.	3.7	32
158	Efficacy of the Long-Acting Octreotide Formulation (Octreotide-Lar) in Patients with Thyrotropin-Secreting Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2849-2853.	3.6	32
159	Computed Tomography of the Anterior Skull Base in Kallmann Syndrome Reveals Specific Ethmoid Bone Abnormalities Associated With Olfactory Bulb Defects. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E537-E546.	3.6	31
160	Medical Treatment of Acromegaly with Dopamine Agonists or Somatostatin Analogs. Neuroendocrinology, 2016, 103, 50-58.	2.5	31
161	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, bvaa205.	0.2	31
162	Estradiol levels in men with congenital hypogonadotropic hypogonadism and the effects ofÂdifferent modalities of hormonal treatment. Fertility and Sterility, 2011, 95, 2324-2329.e3.	1.0	30

#	Article	IF	Citations
163	Inhibin and follicle-stimulating hormone levels in gonadotroph adenomas: evidence of a positive correlation with tumour volume in men. Clinical Endocrinology, 1993, 38, 301-309.	2.4	29
164	Serum PTH reference values established by an automated third-generation assay in vitamin D-replete subjects with normal renal function: consequences of diagnosing primary hyperparathyroidism and the classification of dialysis patients. European Journal of Endocrinology, 2016, 174, 315-323.	3.7	29
165	Normal Pituitary Hypertrophy as a Frequent Cause of Pituitary Incidentaloma: A Follow-Up Study. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3009-3015.	3.6	29
166	Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly. Pituitary, 2008, 11, 129-139.	2.9	28
167	Classification of Patients With GH Disorders May Vary According to the IGF-I Assay. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2844-2852.	3.6	28
168	AIPMutation in Pituitary Adenomas. New England Journal of Medicine, 2011, 364, 1973-1975.	27.0	27
169	A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. European Journal of Endocrinology, 2018, 179, 97-108.	3.7	27
170	Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2964-2974.	3.6	26
171	Free Luteinizing-Hormone Beta-Subunit in Normal Subjects and Patients with Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1397-1402.	3.6	25
172	Absence of activating mutations in the GnRH receptor gene in human pituitary gonadotroph adenomas. European Journal of Endocrinology, 1998, 139, 157-160.	3.7	25
173	Hypogonadotropic hypogonadism as a model of post-natal testicular anti-MÃ¼llerian hormone secretion in humans. Molecular and Cellular Endocrinology, 2003, 211, 51-54.	3.2	25
174	Cabergoline Tapering Is Almost Always Successful in Patients With Macroprolactinomas. Journal of the Endocrine Society, 2017, 1, 221-230.	0.2	25
175	Hypermethylator Phenotype and Ectopic GIP Receptor in GNAS Mutation-Negative Somatotropinomas. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1777-1787.	3.6	25
176	Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201-995). European Journal of Endocrinology, 1991, 124, 487-491.	3.7	25
177	Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly. Pituitary, 2000, 3, 193-197.	2.9	24
178	AIP mutations impair AhR signaling in pituitary adenoma patients fibroblasts and in GH3 cells. Endocrine-Related Cancer, 2016, 23, 433-443.	3.1	24
179	Diabetes insipidus and pregnancy. Annales D'Endocrinologie, 2016, 77, 135-138.	1.4	24
180	Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the BicÃªtre cohort, and review of the literature. Endocrine, 2019, 63, 348-360.	2.3	24

#	Article	IF	Citations
181	Use of radiotherapy after pituitary surgery for non-functioning pituitary adenomas. European Journal of Endocrinology, 2019, 181, D1-D13.	3.7	24
182	Growth hormone effects on cortical bone dimensions in young adults with childhood-onset growth hormone deficiency. Osteoporosis International, 2012, 23, 2219-2226.	3.1	23
183	Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing's syndrome. Annales D'Endocrinologie, 2022, 83, 119-141.	1.4	23
184	Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY. Annales D'Endocrinologie, 2015, 76, 664-670.	1.4	22
185	Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGITÂ® validation study. Pituitary, 2019, 22, 476-487.	2.9	22
186	The Antigonadotropic Activity of a 19-Nor-Progesterone Derivative Is Exerted Both at the Hypothalamic and Pituitary Levels in Women. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4191-4196.	3.6	22
187	Treatment of neurogenic diabetes insipidus. Annales D'Endocrinologie, 2011, 72, 496-499.	1.4	21
188	Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis. European Journal of Endocrinology, 2017, 176, 213-220.	3.7	21
189	An update on clinical care for pregnant women with acromegaly. Expert Review of Endocrinology and Metabolism, 2019, 14, 85-96.	2.4	21
190	Blood microbiota and metabolomic signature of major depression before and after antidepressant treatment: a prospective caseâ€“control study. Journal of Psychiatry and Neuroscience, 2021, 46, E358-E368.	2.4	21
191	Congenital hypogonadotropic hypogonadism/Kallmann syndrome is associated with statural gain in both men and women: a monocentric study. European Journal of Endocrinology, 2020, 182, 185.	3.7	21
192	Comparative Validation of the Growth Hormone-Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency Using a Growth Hormone Assay Conforming to Recent International Recommendations. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3684-3692.	3.6	20
193	Group 2: Adrenal insufficiency: screening methods and confirmation of diagnosis. Annales D'Endocrinologie, 2017, 78, 495-511.	1.4	20
194	Benign cortisol-secreting adrenocortical adenomas produce small amounts of androgens. Clinical Endocrinology, 2007, 66, 778-788.	2.4	19
195	Ovarian macrocysts and gonadotropeâ€“ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease. European Journal of Endocrinology, 2015, 172, 141-149.	3.7	19
196	Pitfalls for detecting interleukin-33 by ELISA in the serum of patients with primary SjÃ¶gren syndrome: comparison of different kits. Annals of the Rheumatic Diseases, 2016, 75, 633-635.	0.9	19
197	The antigonadotropic activity of progestins (19-nortestosterone and 19- norprogesterone derivatives) is not mediated through the androgen receptor. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 4218-4223.	3.6	19
198	Effects of Human Recombinant Luteinizing Hormone and Follicle-Stimulating Hormone in Patients with Acquired Hypogonadotropic Hypogonadism: Study of Sertoli and Leydig Cell Secretions and Interactions. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3239-3244.	3.6	19

#	Article	IF	Citations
199	Pituitary granuloma and pyoderma gangrenosum. Journal of Endocrinological Investigation, 1990, 13, 677-681.	3.3	17
200	Germline Prolactin Receptor Mutation Is Not a Major Cause of Sporadic Prolactinoma in Humans. Neuroendocrinology, 2016, 103, 738-745.	2.5	17
201	Group 5: Acute adrenal insufficiency in adults and pediatric patients. Annales D'Endocrinologie, 2017, 78, 535-543.	1.4	17
202	Resistance to Somatostatin (SRIH) Analog Therapy in Acromegaly. Hormone Research, 1992, 38, 94-99.	1.8	16
203	Diabetes Increases Severe COVID-19 Outcomes Primarily in Younger Adults. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3364-e3368.	3.6	16
204	Emerging drugs for acromegaly. Expert Opinion on Emerging Drugs, 2008, 13, 273-293.	2.4	15
205	Mild pituitary phenotype in 3- and 12-month-old Aip-deficient male mice. Journal of Endocrinology, 2016, 231, 59-69.	2.6	15
206	Pituitary Incidentalomas. , 2003, 13, 124-135.		14
207	Primary amenorrhea revealing an occult progesterone-secreting ovarian tumor. Fertility and Sterility, 2008, 90, 1198.e1-1198.e5.	1.0	14
208	Mutational status of EGFR, BRAF, PI3KCA and JAK2 genes in endocrine tumors. International Journal of Cancer, 2009, 124, 751-753.	5.1	14
209	Prolactinoma. , 2017, , 467-514.		14
210	Effects of cortisol on the heart: characterization of myocardial involvement in cushing's disease by longitudinal cardiac MRI T1 mapping. Journal of Magnetic Resonance Imaging, 2017, 45, 147-156.	3.4	14
211	Even after priming with ovarian steroids or pulsatile gonadotropin- releasing hormone administration, naltrexone is unable to induce ovulation in women with functional hypothalamic amenorrhea. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 2102-2107.	3.6	14
212	Thyrotropin-releasing hormone (TRH) binding sites and thyrotropin response to TRH are regulated by thyroid hormones in human thyrotropic adenomas. European Journal of Endocrinology, 1994, 130, 559-564.	3.7	13
213	Screening of acromegaly in adults with obstructive sleep apnea: is it worthwhile?. Endocrine, 2018, 61, 4-6.	2.3	13
214	GnRH stimulation testing and serum inhibin B in males: insufficient specificity for discriminating between congenital hypogonadotropic hypogonadism from constitutional delay of growth and puberty. Human Reproduction, 2020, 35, 2312-2322.	0.9	13
215	Somatostatin receptor ligands induce TSH deficiency in thyrotropin-secreting pituitary adenoma. European Journal of Endocrinology, 2021, 184, 1-8.	3.7	13
216	Ovarian dysfunction by activating mutation of GS alpha: McCune-Albright syndrome as a model. Annales D'Endocrinologie, 2010, 71, 210-213.	1.4	12

#	Article	IF	Citations
217	In-frame seven amino-acid duplication in AIP arose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantism. European Journal of Endocrinology, 2017, 177, 257-266.	3.7	12
218	Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data. Drug Design, Development and Therapy, 2017, Volume 11, 1489-1495.	4.3	12
219	Sensitivity and specificity of the macimorelin test for diagnosis of AGHD. Endocrine Connections, 2021, 10, 76-83.	1.9	12
220	Pituitary adenoma in patients with multiple endocrine neoplasia type 1: a cohort study. European Journal of Endocrinology, 2021, 185, 863-873.	3.7	12
221	Chromogranin A as serum marker of pituitary adenomas. Clinical Endocrinology, 2003, 59, 644-648.	2.4	11
222	Cardiovascular complications of acromegaly. Annales D'Endocrinologie, 2021, 82, 206-209.	1.4	11
223	Management of early postoperative diabetes insipidus with parenteral desmopressin. European Journal of Endocrinology, 1988, 117, 513-516.	3.7	10
224	Hyperfunctioning unilateral adrenal macronodule in three patients with Cushing's disease: hormonal and imaging characterization. European Journal of Endocrinology, 1993, 129, 284-290.	3.7	10
225	Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits?. European Journal of Endocrinology, 1997, 136, 359-361.	3.7	10
226	Less is more risky? Growth hormone and insulin-like growth factor 1 levels and cardiovascular risk. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 650-651.	2.8	10
227	Treatment of acromegaly has substantial effects on body composition: a long-term follow-up study. European Journal of Endocrinology, 2022, 186, 173-181.	3.7	10
228	Prolactin immunoassay: does the high-dose hook effect still exist?. Pituitary, 2022, 25, 653-657.	2.9	10
229	Contribution of functionally assessed GHRHR mutations to idiopathic isolated growth hormone deficiency in patients without GH1 mutations. Human Mutation, 2019, 40, 2033-2043.	2.5	9
230	Outcome of pituitary hormone deficits after surgical treatment of nonfunctioning pituitary macroadenomas. Endocrine, 2021, 73, 166-176.	2.3	9
231	Reference values for IGF-I serum concentration in an adult population: use of the VARIETE cohort for two new immunoassays. Endocrine Connections, 2021, 10, 1027-1034.	1.9	9
232	Central diabetes insipidus and pituitary stalk thickening in adults: distinction of neoplastic from non-neoplastic lesions. European Journal of Endocrinology, 2020, 183, 95-105.	3.7	9
233	McCune-Albright syndrome in adulthood. Pediatric Endocrinology Reviews, 2007, 4 Suppl 4, 453-62.	1.2	9
234	Hepato-pancreato-biliary lesions are present in both Carney complex and McCune Albright syndrome. Molecular and Cellular Endocrinology, 2014, 382, 344-345.	3.2	8

#	Article	IF	Citations
235	Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study. Endocrine, 2021, 71, 158-167.	2.3	8
236	International Multicenter Validation Study of the SAGITÂ® Instrument in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3555-3568.	3.6	8
237	Apoplexy of microprolactinomas during pregnancy: report of five cases and review of the literature. European Journal of Endocrinology, 2021, 185, 99-108.	3.7	8
238	Efficacy and safety of dopamine agonists in patients treated with antipsychotics and presenting a macroprolactinoma. European Journal of Endocrinology, 2020, 183, 221-231.	3.7	8
239	TORSADE DE POINTES AND Q-T PROLONGATION IN SECONDARY HYPOTHYROIDISM. Lancet, The, 1988, 332, 170-171.	13.7	7
240	Other Pituitary Conditions and Pregnancy. Endocrinology and Metabolism Clinics of North America, 2019, 48, 583-603.	3.2	7
241	Cortisol and Aldosterone Responses to Hypoglycemia and Na Depletion in Women With Non-Classic 21-Hydroxylase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 55-64.	3.6	7
242	Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas. Pituitary, 2022, 25, 64-73.	2.9	7
243	Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe. European Journal of Endocrinology, 2022, 186, K17-K24.	3.7	7
244	Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3313-e3320.	3.6	7
245	Does attainment of target levels of growth hormone and insulin-like growth factor I improve acromegaly prognosis?. Nature Clinical Practice Endocrinology and Metabolism, 2009, 5, 70-71.	2.8	6
246	The heart in growth hormone (GH) deficiency and the cardiovascular effects of GH. Annales D'Endocrinologie, 2021, 82, 210-213.	1.4	6
247	Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312) Tj ETQq1 1 0.784314 rgBT /O	1.4	6
248	Reproductive Phenotypes in Men With Acquired or Congenital Hypogonadotropic Hypogonadism: A Comparative Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2812-e2824.	3.6	6
249	Heart failure and octreotide in acromegaly. Lancet, The, 1992, 339, 242-243.	13.7	5
250	Transsphenoidal resection for pituitary adenoma in elderly versus younger patients: a systematic review and meta-analysis. Acta Neurochirurgica, 2020, 162, 1297-1308.	1.7	5
251	IGF-I Variability Over Repeated Measures in Patients With Acromegaly Under Long-Acting Somatostatin Receptor Ligands. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3644-e3653.	3.6	5
252	Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 1: Diagnostic and Clinical Issues. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 1133-1143.	1.2	4

#	Article	IF	Citations
253	Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 2: Therapeutic Issues. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 1144-1155.	1.2	4
254	Epicardial and Pericardial Adiposity Without Myocardial Steatosis in Cushing Syndrome. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3505-3514.	3.6	4
255	Cost-Utility of Acromegaly Pharmacological Treatments in a French Context. Frontiers in Endocrinology, 2021, 12, 745843.	3.5	4
256	Prolactin Assays and Regulation of Secretion: Animal and Human Data. Contemporary Endocrinology, 2019, , 55-78.	0.1	3
257	Pituitary Stalk Enlargement in Adults. Neuroendocrinology, 2020, 110, 809-821.	2.5	3
258	Impact of Growth Hormone-Lowering Treatments on Heart Function in Acromegaly. Growth Hormone, 2001, , 45-57.	0.2	3
259	Classification et physiopathologie des adÃ©nomes hypophysaires. Bulletin De L'Academie Nationale De Medecine, 2009, 193, 1543-1556.	0.0	3
260	CLINICALLY NON-FUNCTIONING PITUITARY ADENOMAS. Presse Medicale, 2021, 50, 104086.	1.9	3
261	Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. European Journal of Endocrinology, 2012, 167, 887-887.	3.7	2
262	Fractionated stereotactic radiotherapy: an interesting alternative to stereotactic radiosurgery in acromegaly. Endocrine, 2015, 50, 529-530.	2.3	2
263	Diagnosis of acromegaly: black, whiteâ€¦ and sometimes gray!. Archives of Endocrinology and Metabolism, 2016, 60, 505-506.	0.6	2
264	Measurement of Plasma Free Luteinizing Hormone Â-Subunit in Women. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2293-2298.	3.6	2
265	Preface. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, vii-viii.	4.7	1
266	Physiopathology, Diagnosis, and Treatment of Nonfunctioning Pituitary Adenomas. Endocrinology, 2018, , 93-128.	0.1	1
267	Endocrinological diagnosis and treatment of TSH-secreting pituitary adenomas. , 2021, , 245-260.		1
268	Primary Amenorrhea Due to Constant High Progesterone Level Revealing a Leydig Cell Ovarian Tumor. Fertility and Sterility, 2005, 84, S161-S162.	1.0	0
269	Update in pituitary disorders. Best Practice and Research in Clinical Endocrinology and Metabolism, 2019, 33, 101308.	4.7	0
270	McCune-Albright Syndrome in Clinical Practice. Endocrinology, 2021, , 377-386.	0.1	0

#	Article	IF	Citations
271	Response to Letter to the Editor from Woolcott and Castilla-BancayÃ¡n: â€œDiabetes Increases Severe COVID-19 Outcomes Primarily in Younger Adultsâ€. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e5277-e5278.	3.6	0
272	Response to Letter to the Editor from Soghomonian: â€œEpicardial and Pericardial Adiposity Without Myocardial Steatosis in Cushing Syndromeâ€. Journal of Clinical Endocrinology and Metabolism, 2021, , .	3.6	0
273	McCune-Albright Syndrome in Clinical Practice. Endocrinology, 2021, , 1-10.	0.1	0
274	Surgical Approaches in 84 Patients with Insulinomas in Multiple Endocrine Neoplasia Type 1 (MEN 1).. , 2010, , P2-88-P2-88.		0
275	Efficacy of Cabergoline in the Treatment of Acromegaly: A Meta-Analysis.. , 2010, , P3-268-P3-268.		0
276	Diagnosis of secondary hypoadrenalism. Clinical Endocrinology, 1996, 45, 122-123.	2.4	0
277	Physiopathology, Diagnosis, and Treatment of Nonfunctioning Pituitary Adenomas. Endocrinology, 2018, , 1-37.	0.1	0
278	Therapy for Acromegaly. , 2018, , 230-247.		0
279	MON-244 GnRH Test Does Not Efficiently Discriminate Congenital Isolated Hypogonadotropic Hypogonadism from Constitutional Delay of Growth and Puberty in Males. Journal of the Endocrine Society, 2019, 3, .	0.2	0
280	Pituitary stalk thickening: neoplastic or not? - authorâ€™s response to the letter by Wang et al.. European Journal of Endocrinology, 2020, 183, L23-L25.	3.7	0
281	Hypertension in Acromegaly. Updates in Hypertension and Cardiovascular Protection, 2020, , 167-179.	0.1	0
282	Recent insights in pituitary diseases.. Presse Medicale, 2021, 50, 104094.	1.9	0
283	Second brain tumours after pituitary irradiation: lower risk than once thought. Lancet Diabetes and Endocrinology,the, 2022, 10, 552-554.	11.4	0